LEF1 antibody (AA 256-297)

Catalog No. ABIN187662

This anti-LEF1 antibody is a Mouse Monoclonal antibody detecting LEF1 in WB. Suitable for Human.

Quick Overview for LEF1 antibody (AA 256-297) (ABIN187662)

Target: LEF1 (Lymphoid Enhancer-Binding Factor 1 (LEF1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This LEF1 antibody is un-conjugated

Application: Western Blotting (WB)

Clone: 2F4-1D10

Product Details anti-LEF1 Antibody

Binding Specificity: AA 256-297

Specificity: This antibody detects all isoforms of LEF-1 by Western blot. Does not crossreact with TCF-1 or TCF-4. Species Reactivity: Human. Others not tested.

Sterility: 0.2 μm filtered

Immunogen: Recombinant full length LEF-1 protein.

Isotype: IgG1

Application Details

Application Notes: Western blot The optimal dilution for a specific application should be determined by the researcher.

Restrictions: For Research Use only

Handling

Buffer: Purified antibody 100 µg at 1.0 mg/mL. Provided as 0.2 µm sterile filtered solution in phosphate buffered saline with 0.08% sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Target Details for LEF1

Target: LEF1 (Lymphoid Enhancer-Binding Factor 1 (LEF1))

Alternative Name: LEF1

Background: Lymphoid Enhancer Factor-1 (LEF-1) is an HMG 1/2-like DNA binding/bending protein and is a member of the LEF/TCF transcription factor family. There are four LEF/TCF family members in mammalian systems (LEF-1, TCF-1, TCF-3 and TCF-4), and orthologs to these factors have been identified in many different species. LEF/TCFs are downstream mediators of Wnt/Wingless signals. Wnt signaling drives cell polarity, cell fate and cell growth decisions in embryonic tissues and in post-natal tissues that continue to develop from mitotically active stem cell precursors. Misregulation of Wnt signaling is also implicated as a root cause of many different cancers, such as colon cancer, melanoma, breast cancer, prostate cancer and others.

Pathways: WNT Signaling, Intracellular Steroid Hormone Receptor Signaling Pathway, Regulation of Hormone Metabolic Process, Nuclear Hormone Receptor Binding, Chromatin Binding